Kateryna Filonenko

Dr. Kateryna Filonenko

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2021 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
TSTetiana Skrypets
Tetiana Skrypets
CFCristina Ferrari
Cristina Ferrari
LNLuca Nassi
Luca Nassi
GCGloria Margiotta Casaluci
Gloria Margiotta Casaluci
BPBenedetta Puccini
Benedetta Puccini
carla minoiacarla minoia
carla minoia
The detection of gastrointestinal (GI) involvement in Mantle Cell Lymphoma is often underestimated and may have an impact on outcome and clinical management. We aimed to evaluate whether baseline 18F-FDG PET/CT presents comparable results to endoscopic biopsy in the diagnosis of GI localizations. In our retrospective cohort of 79 patients, sensitivity and specificity of 18F-FDG PET/CT were low for the stomach, with a fair concordance (k = 0.32), while higher concordance with pathologic results (k = 0.65) was detected in the colorectal tract. Thus, gastric biopsy remains helpful in the staging of MCL despite 18F-FDG PET/CT, while colonoscopy could be omitted in asymptomatic patients. The validation of our data in prospective cohorts is desirable

19 August 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
KFKateryna Filonenko
Kateryna Filonenko
Marco PicardiMarco Picardi
Marco Picardi
Stephane ChauvieStephane Chauvie
Stephane Chauvie
AFAndrea Riccardo Filippi
Andrea Riccardo Filippi
MPMaria Cristina Pirosa
Maria Cristina Pirosa
Jan ZauchaJan Zaucha
Jan Zaucha
Radiation-free treatment for early-stage classic Hodgkin lymphoma (eHL) has been shown to be less effective than standard combined-modality treatment (CMT; chemotherapy plus involved-node radiotherapy (INRT)), which achieves long-term disease control of 94–95%. Approximately 70% of patients can be cured with chemotherapy alone, whereas about 5% fail CMT. Identifying patients who can safely receive chemotherapy alone and those requiring intensified CMT could enable a risk-adapted treatment strategy. The RAFTING trial (NCT04866654; EudraCT 2020-002382-33) is an international, prospective, phase 2, non-inferiority study enrolling patients 18–70 years, stage I–IIA eHL without bulky disease, B symptoms, or extranodal involvement. Low-risk (LR) patients are defined by total metabolic tumor volume (TMTV) <84 mL and negative PET-2. Those with at least one modified EORTC (mEORTC) risk factor, in which bulky disease is replaced by a large nodal mass (5–10 cm), receive four ABVD cycles, while those without risk factors receive two ABVD cycles alone. High-risk (HR) patients, defined by TMTV ≥84 mL and/or positive PET-2, receive “triple therapy”: 4 ABVD cycles, INRT (20/30 Gy), and nivolumab (240 mg q2w, ≤doses). LR patients are monitored using cfDNA. Limited relapse is treated with INRT (36 Gy) and nivolumab. The RAFTING trial is the first prospective eHL study to personalize treatment using TMTV and PET-2. It aims to omit radiotherapy in LR patients, intensify treatment in HR patients, and spare relapsed LR patients high-dose chemotherapy and autologous transplantation. CfDNA is being evaluated as a relapse marker. Despite the protocol’s complexity, this study exemplifies personalized medicine and could transform treatment practices.

1 January 2025 in Advances in Hematology
Verified
Journal Article
Open access
KFKateryna Filonenko
Kateryna Filonenko
YSYana Stepanishyna
Yana Stepanishyna
NSNazar Shokun
Nazar Shokun
AMArina Martynchyk
Arina Martynchyk
YKYevhen Kushchevyi
Yevhen Kushchevyi
JZJan Maciej Zaucha
Jan Maciej Zaucha
Background: There is no strong evidence supporting brentuximab vedotine (BV) efficacy as a salvage regimen for relapsed/refractory Hodgkin’s lymphoma (R/R HL) patients before autologous hematopoietic cell transplantation (auto‐HCT). Methods: We performed multicenter retrospective analysis of efficiency of treatment with the BV monotherapy as salvage regimen versus standard salvage chemotherapy (sCT) in 44 patients with R/R HL from a high‐risk group. Results: Twenty‐six patients (59.1%) had primary refractory disease. Nineteen patients (43.2%) received BV salvage treatment before auto‐HCT, and 12 (63.6%) achieved complete response (CR) that counts 27.3% of the whole study cohort. There was no difference in the CR rate, 2‐year progression‐free survival, and 2‐year overall survival after BV salvage and sCT (63.2% vs. 60%, respectively, p = 0.35; 88.2% vs. 80.7%, p = 0.655; 94.1% vs. 100%, p = 0.735, respectively). There was no difference in neuropathy of all grades, including Grades 2‐3 between groups. Conclusions: The BV as a salvage treatment showed quite high efficiency. Despite a worse clinical characteristic of the BV group, there were no significant differences in the outcomes of the auto‐HCT with respect to the salvage regimen (BV versus sCT) used before auto‐HCT. Our results suggest that BV before auto‐HCT in patients refractory to standard 2nd line treatment equalizes their prognosis to the patient sensitive to standard CT with the same tolerance and toxicity.